Correction: Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization.

Correction: Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization.

Bibliographic Details
Main Authors:	Rajesh Ringe, Lipsa Das, Ipsita Choudhary, Deepak Sharma, Ramesh Paranjape, Virander Singh Chauhan, Jayanta Bhattacharya
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3795157

Similar Items

Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization.
by: Rajesh Ringe, et al.
Published: (2012-01-01)

Correction: Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization
Published: (2013-01-01)

Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities
by: Ranajoy Mullick, et al.
Published: (2021-05-01)

Broadly neutralizing antibodies in HIV-1 treatment and prevention
by: Rajesh Kumar, et al.
Published: (2018-08-01)

Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C <it>env </it>clones obtained at different time points from antiretroviral naïve Indian patients with recent infection
by: Bhattacharya Jayanta, et al.
Published: (2010-09-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
by: Labranche, CC, et al.
Published: (2018)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2018-11-01)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-03-01)

HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
by: Laurent Verkoczy, et al.
Published: (2014-05-01)

Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies
by: Maya Contreras, et al.
Published: (2024-02-01)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
by: Elise Landais, et al.
Published: (2018-09-01)

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
by: Marianne Boutin, et al.
Published: (2022-06-01)

Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity
by: Dai Zhang, et al.
Published: (2019-05-01)

Broadly Neutralizing Synthetic Cannabinoid Vaccines
by: Mingliang Lin, et al.
Published: (2020-12-01)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
by: Dan Hu, et al.
Published: (2019-06-01)

Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
by: Jyoti Sutar, et al.
Published: (2021-01-01)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
by: LaBranche, C, et al.
Published: (2019)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-09-01)

The expanding array of HIV broadly neutralizing antibodies
by: Laura E. McCoy
Published: (2018-10-01)

Broadly Neutralizing Antibodies for HIV-1 Prevention
by: Stephen R. Walsh, et al.
Published: (2021-07-01)

Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma.
by: Nitesh Mishra, et al.
Published: (2021-09-01)

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-12-01)

Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
by: Lucia Reh, et al.
Published: (2018-01-01)

Computational Prediction of Broadly Neutralizing HIV-1 Antibody Epitopes from Neutralization Activity Data
by: Ferguson, Andrew L., et al.
Published: (2014)

The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies
by: Sok, Devin, et al.
Published: (2014)

Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.
by: Andrew L Ferguson, et al.
Published: (2013-01-01)

Contribution of rare mutational outcomes to broadly neutralizing antibodies
by: Feng Anqi, et al.
Published: (2022-06-01)

Optimizing immunization protocols to elicit broadly neutralizing antibodies
by: Sprenger, Kayla G, et al.
Published: (2021)

Cross-reactive broadly neutralizing antibodies: timing is everything
by: Zelda eEuler, et al.
Published: (2012-07-01)

Broad dengue neutralization in mosquitoes expressing an engineered antibody.
by: Anna Buchman, et al.
Published: (2020-01-01)

Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana
by: Natasha O. Moraka, et al.
Published: (2023-10-01)

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
by: Ben-Jiang Ma, et al.
Published: (2011-09-01)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
by: Guo D, et al.
Published: (2012-09-01)

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.
by: Jing Yang, et al.
Published: (2023-11-01)

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
by: Jing Yang, et al.
Published: (2023-11-01)

Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.
by: Scott A McKinley, et al.
Published: (2014-01-01)

Correction: The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies.
by: Devin Sok, et al.
Published: (2013-12-01)

Identification of a Neutralizing Monoclonal Antibody That Recognizes a Unique Epitope on Domain III of the Envelope Protein of Tembusu Virus
by: Shenghua Qu, et al.
Published: (2020-06-01)

The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein
by: Scott A. Smith, et al.
Published: (2013-12-01)

Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B′ Infected Plasma Donor with Broadly Neutralizing Activity
by: Yuanyuan Hu, et al.
Published: (2021-03-01)